JPRN-UMIN000008780Completed未知
An Efficacy Study of Esomeprazole in Patients with Reflux Esophagitis Poorly Responsive to Lansoprazole - An Efficacy Study of Esomeprazole in Patients with Reflux Esophagitis Poorly Responsive to Lansoprazole (CHANGE-L Study)
Research Organization for Gastroenterological Disease Treatment0 sites200 target enrollmentStarted: December 1, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) Patients with a history of hypersensitivity to the study drugs. (2) Patients with a history of digestive tract resection or vagotomy. (3) Patients with warning findings such as vomiting, gastrointestinal hemorrhage (including findings such as hematemesis, melena, and anemia) and acute weight loss. (4) Patients with concurrent peptic ulcer (excluding the scarred stage). (5) Patients with a past or current history of any of the following diseases: Zollinger-Ellison syndrome, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), esophageal stenosis, esophageal achalasia, malabsorption, or cerebrovascular disorder such as cerebral hemorrhage and cerebral infarction. (6) Patients treated for H. pylori eradication within 6 months before the time of eligibility check. (7) Patients who may have difficulty participating in the study owing to serious complications such as liver, renal, or cardiac diseases. (8) Patients with a confirmed or possible malignancy. (9) Women who are pregnant, lactating, or possibly pregnant. (10) Patients who are on proton pump inhibitors other than lansoprazole. (11) Patients who need to continue treatment with drugs for which interactions with the study drugs are anticipated. (12) Patients who are on or need to continue treatment with drugs that are assumed to have an effect on study results. *However, patients may be enrolled in the study if such drugs are interrupted for 1 week prior to the investigation of the symptoms or are switched to other treatment. (13) Patients who are determined by the investigator or subinvestigator to be not suitable to be enrolled in the study due to other reasons.
Investigators
Similar Trials
Completed
Not Applicable
An Efficacy Study of Esomeprazole in Patients with Reflux Esophagitis Poorly Responsive to Rabeprazolereflux esophagitisJPRN-UMIN000008779Research Organization for Gastroenterological Disease Treatment200
Recruiting
Phase 3
The evaluation of esomeprazole efficacy in treatment of early onset pre-eclampsiaPreeclampsia.Eclampsia in pregnancyIRCT2017082333680N2Vice chancellor for research, Mashhad University of Medical Sciences46
Completed
Not Applicable
Investigation of the efficacy of Esomeprazole for 8 weeks to the proton pomp inhibitor (PPI)-resistant gastro-esophageal reflux disease (GERD) patientsGastroesophagealJPRN-UMIN000012000ationalOrganizationHospital Fukuyama medical center50
Completed
Not Applicable
A prospective study of esomeprazole treatment for ulcer healing after gastric endoscopic submucosal dissectioearly gastric cancerJPRN-UMIN000010786niversity of Fukui Hospital200
Active, not recruiting
Not Applicable
Effect of Mycophenolate Mofetil in presence of antacidsCTRI/2020/06/025939Centre for Arthritis and Rheumatism Excellence CARE